tiprankstipranks
Gilead Sciences (GILD)
NASDAQ:GILD
US Market
GILD
Gilead Sciences
RESEARCH TOOLSreports
Want to see GILD full AI Analyst Report?

Gilead Sciences (GILD) Stock Forecast & Price Target

13,981 Followers
See the Price Targets and Ratings of:

GILD Analyst Ratings

Strong Buy
21Ratings
Strong Buy
17 Buy
4 Hold
0 Sell
Based on 21 analysts giving stock ratings to
Gilead
Sciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GILD Stock 12 Month Forecast

Average Price Target

$158.05
▲(6.24% Upside)
Based on 21 Wall Street analysts offering 12 month price targets for Gilead Sciences in the last 3 months. The average price target is $158.05 with a high forecast of $177.00 and a low forecast of $123.00. The average price target represents a 6.24% change from the last price of $148.77.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"108":"$108","143":"$143","178":"$178","125.5":"$125.5","160.5":"$160.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":177,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$177.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":158.05263157894737,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$158.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":123,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$123.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[108,125.5,143,160.5,178],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,130.21,133.80923076923077,137.40846153846155,141.0076923076923,144.6069230769231,148.20615384615385,151.8053846153846,155.4046153846154,159.00384615384615,162.6030769230769,166.2023076923077,169.80153846153846,173.40076923076924,{"y":177,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,130.21,132.35174089068826,134.49348178137652,136.63522267206477,138.77696356275305,140.9187044534413,143.06044534412956,145.20218623481782,147.34392712550607,149.48566801619432,151.62740890688258,153.76914979757086,155.91089068825912,{"y":158.05263157894737,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,130.21,129.65538461538463,129.10076923076923,128.54615384615386,127.99153846153847,127.43692307692308,126.88230769230769,126.32769230769232,125.77307692307693,125.21846153846154,124.66384615384615,124.10923076923078,123.55461538461539,{"y":123,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":110.306,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 66,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.101,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.08,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.559,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.014,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.155,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":148.208,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.383,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.79,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.244,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.97,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.21,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$177.00Average Price Target$158.05Lowest Price Target$123.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on GILD
Salim Syed
Mizuho Securities
Mizuho Securities
$170
Buy
14.27%
Upside
Reiterated
08/31/26
Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (NASDAQ: VERA) and Gilead Sciences (NASDAQ: GILD)
Truist Financial Analyst forecast on GILD
Gregory Renza
Truist Financial
Truist Financial
―
Buy
―
Reiterated
08/28/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Scotiabank Analyst forecast on GILD
Louise Chen
Scotiabank
Scotiabank
$177
Buy
18.98%
Upside
Reiterated
08/28/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilon Health (NYSE: AGL) and Gilead Sciences (NASDAQ: GILD)
BMO Capital Analyst forecast on GILD
Evan Seigerman
BMO Capital
BMO Capital
$174
Buy
16.96%
Upside
Reiterated
08/27/26
Analysts Are Bullish on These Healthcare Stocks: Globus Medical (GMED), Biohaven Ltd. (BHVN)
Morgan Stanley Analyst forecast on GILD
Terence Flynn
Morgan Stanley
Morgan Stanley
$165
Buy
10.91%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: AC Immune SA (NASDAQ: ACIU) and Gilead Sciences (NASDAQ: GILD)
Barclays Analyst forecast on GILD
Emily Field
Barclays
Barclays
$145
Hold
-2.53%
Downside
Reiterated
08/13/26
Gilead Sciences (GILD) Gets a Hold from Barclays
J.P. Morgan Analyst forecast on GILD
Chris Schott
J.P. Morgan
J.P. Morgan
$160
Buy
7.55%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Staar Surgical (NASDAQ: STAA) and Elanco Animal Health (NYSE: ELAN)
Maxim Group Analyst forecast on GILD
Michael Okunewitch
Maxim Group
Maxim Group
$165
Buy
10.91%
Upside
Reiterated
08/06/26
Gilead: Strong HIV and Oncology Growth Underpins Reiterated Buy Rating and Unchanged $165 Price Target
Needham Analyst forecast on GILD
Joseph Stringer
Needham
Needham
$170
Buy
14.27%
Upside
Reiterated
08/05/26
Gilead Buy Rating Reaffirmed on Strong HIV-Driven Growth and Raised Revenue Outlook; $170 Price Target Maintained
Wells Fargo Analyst forecast on GILD
Mohit Bansal
Wells Fargo
Wells Fargo
$165
Buy
10.91%
Upside
Assigned
08/05/26
Gilead Sciences (GILD) Gets a Buy from Wells Fargo
Bank of America Securities Analyst forecast on GILD
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$162
Buy
8.89%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: InfuSystem Holdings (NYSE MKT: INFU), Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Gilead Sciences (NASDAQ: GILD)
Evercore ISI Analyst forecast on GILD
Umer Raffat
Evercore ISI
Evercore ISI
―
Buy
―
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Beam Therapeutics (NASDAQ: BEAM)
TD Cowen Analyst forecast on GILD
Tyler Van Buren
TD Cowen
TD Cowen
$160
Buy
7.55%
Upside
Assigned
08/04/26
Gilead Sciences: Strong Core Performance and Upgraded HIV Outlook Underpin Buy Rating and Earnings Power
Citi Analyst forecast on GILD
Geoff Meacham
Citi
Citi
$165
Buy
10.91%
Upside
Reiterated
08/04/26
Gilead Sciences (GILD) Gets a Buy from Citi
RBC Capital Analyst forecast on GILD
Brian Abrahams
RBC Capital
RBC Capital
$120→$123
Hold
-17.32%
Downside
Reiterated
08/04/26
RBC Capital Sticks to Its Hold Rating for Gilead Sciences (GILD)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on GILD
Salim Syed
Mizuho Securities
Mizuho Securities
$170
Buy
14.27%
Upside
Reiterated
08/31/26
Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (NASDAQ: VERA) and Gilead Sciences (NASDAQ: GILD)
Truist Financial Analyst forecast on GILD
Gregory Renza
Truist Financial
Truist Financial
―
Buy
―
Reiterated
08/28/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Scotiabank Analyst forecast on GILD
Louise Chen
Scotiabank
Scotiabank
$177
Buy
18.98%
Upside
Reiterated
08/28/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilon Health (NYSE: AGL) and Gilead Sciences (NASDAQ: GILD)
BMO Capital Analyst forecast on GILD
Evan Seigerman
BMO Capital
BMO Capital
$174
Buy
16.96%
Upside
Reiterated
08/27/26
Analysts Are Bullish on These Healthcare Stocks: Globus Medical (GMED), Biohaven Ltd. (BHVN)
Morgan Stanley Analyst forecast on GILD
Terence Flynn
Morgan Stanley
Morgan Stanley
$165
Buy
10.91%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: AC Immune SA (NASDAQ: ACIU) and Gilead Sciences (NASDAQ: GILD)
Barclays Analyst forecast on GILD
Emily Field
Barclays
Barclays
$145
Hold
-2.53%
Downside
Reiterated
08/13/26
Gilead Sciences (GILD) Gets a Hold from Barclays
J.P. Morgan Analyst forecast on GILD
Chris Schott
J.P. Morgan
J.P. Morgan
$160
Buy
7.55%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Staar Surgical (NASDAQ: STAA) and Elanco Animal Health (NYSE: ELAN)
Maxim Group Analyst forecast on GILD
Michael Okunewitch
Maxim Group
Maxim Group
$165
Buy
10.91%
Upside
Reiterated
08/06/26
Gilead: Strong HIV and Oncology Growth Underpins Reiterated Buy Rating and Unchanged $165 Price Target
Needham Analyst forecast on GILD
Joseph Stringer
Needham
Needham
$170
Buy
14.27%
Upside
Reiterated
08/05/26
Gilead Buy Rating Reaffirmed on Strong HIV-Driven Growth and Raised Revenue Outlook; $170 Price Target Maintained
Wells Fargo Analyst forecast on GILD
Mohit Bansal
Wells Fargo
Wells Fargo
$165
Buy
10.91%
Upside
Assigned
08/05/26
Gilead Sciences (GILD) Gets a Buy from Wells Fargo
Bank of America Securities Analyst forecast on GILD
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$162
Buy
8.89%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: InfuSystem Holdings (NYSE MKT: INFU), Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Gilead Sciences (NASDAQ: GILD)
Evercore ISI Analyst forecast on GILD
Umer Raffat
Evercore ISI
Evercore ISI
―
Buy
―
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Beam Therapeutics (NASDAQ: BEAM)
TD Cowen Analyst forecast on GILD
Tyler Van Buren
TD Cowen
TD Cowen
$160
Buy
7.55%
Upside
Assigned
08/04/26
Gilead Sciences: Strong Core Performance and Upgraded HIV Outlook Underpin Buy Rating and Earnings Power
Citi Analyst forecast on GILD
Geoff Meacham
Citi
Citi
$165
Buy
10.91%
Upside
Reiterated
08/04/26
Gilead Sciences (GILD) Gets a Buy from Citi
RBC Capital Analyst forecast on GILD
Brian Abrahams
RBC Capital
RBC Capital
$120→$123
Hold
-17.32%
Downside
Reiterated
08/04/26
RBC Capital Sticks to Its Hold Rating for Gilead Sciences (GILD)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Gilead Sciences

3 Months
Courtney BreenBernstein
Success Rate
15/19 ratings generated profit
79%
Average Return
+7.57%
Copying Courtney Breen's trades and holding each position for 3 Months would result in 78.95% of your transactions generating a profit, with an average return of +7.57% per trade.
1 Year
Courtney BreenBernstein
Success Rate
19/19 ratings generated profit
100%
Average Return
+24.17%
Copying Courtney Breen's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +24.17% per trade.
2 Years
Chris SchottJ.P. Morgan
Success Rate
25/25 ratings generated profit
100%
Average Return
+49.19%
Copying Chris Schott's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +49.19% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GILD Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
0
Buy
48
41
58
53
56
Hold
13
12
13
13
11
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
61
53
71
66
67
In the current month, GILD has received 56 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. GILD average Analyst price target in the past 3 months is 158.05.
Each month's total comprises the sum of three months' worth of ratings.

GILD Financial Forecast

GILD Earnings Forecast

Next quarter’s earnings estimate for GILD is $2.12 with a range of $1.90 to $2.35. The previous quarter’s EPS was -$6.75. GILD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.
Next quarter’s earnings estimate for GILD is $2.12 with a range of $1.90 to $2.35. The previous quarter’s EPS was -$6.75. GILD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.

GILD Sales Forecast

Next quarter’s sales forecast for GILD is $7.76B with a range of $7.52B to $7.96B. The previous quarter’s sales results were $7.82B. GILD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.
Next quarter’s sales forecast for GILD is $7.76B with a range of $7.52B to $7.96B. The previous quarter’s sales results were $7.82B. GILD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.

GILD Stock Forecast FAQ

What is GILD’s average 12-month price target, according to analysts?
Based on analyst ratings, Gilead Sciences’s 12-month average price target is 158.05.
    What is GILD’s upside potential, based on the analysts’ average price target?
    Gilead Sciences has 6.24% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is GILD a Buy, Sell or Hold?
          Gilead Sciences has a consensus rating of Strong Buy which is based on 17 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Gilead Sciences’s price target?
            The average price target for Gilead Sciences is 158.05. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $177.00 ,the lowest forecast is $123.00. The average price target represents 6.24% Increase from the current price of $148.77.
              What do analysts say about Gilead Sciences?
              Gilead Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.
                How can I buy shares of GILD?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.